Definium Therapeutics Inc. research snapshot
DFTX AI stock analysis reads Definium Therapeutics as a pre-revenue clinical-stage biopharmaceutical company focused on psychedelic medicine for brain health disorders. The analysis is not a certain price prediction. At the July 12, 2026 cutoff, the latest verified close was $47.07, market capitalization was about $6.25 billion, and the stock traded near its 52-week high after a Phase 3 win for DT120 in major depressive disorder drove a sharp rally from the $8 level. The core question is whether Definium can secure FDA approval for DT120, commercialize successfully, and extend its pipeline into ASD and other indications while managing a cash burn rate that consumed $237 million over the trailing twelve months. This is informational research and not investment advice.
Current price
$47.07
Market cap
$6.25 billion
AI score
50 / 100
Rating
High-risk pre-revenue biotech with positive Phase 3 catalyst
Trend status
Strong uptrend from 52-week low, near all-time high after Phase 3 win
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Pre-revenue clinical-stage biotech developing psychedelic therapies (DT120 LSD-based for MDD/GAD, DT402 R-MDMA for ASD) with a positive Phase 3 MDD readout but no approved products or revenue. | Low |
| Moat | Patent protection on DT120 ODT formulation and DT402 enantiomer, FDA regulatory barriers, and first-mover positioning in psychedelic medicine. The moat is unproven and depends on successful FDA approval and commercial adoption. | Low |
| Management | CEO Robert Barrow leads a team with biotech and psychedelic medicine experience. Recent $805 million upsized public offering demonstrates institutional confidence. Pipeline execution and capital allocation track record is limited. | Medium-low |
| Financial trend | No revenue. TTM operating expenses were roughly $193 million with a net loss of $237 million. Cash balance of $373 million provides runway into 2027. Annual cash burn is accelerating with R&D spending growing from $29.8M (Q2 2025) to $41.5M (Q1 2026). | Medium |
| Valuation | At $6.25B market cap with no revenue or earnings, valuation is entirely based on pipeline probability-weighted expectations. Comparable psychedelic biotech peers (CMPS $900M, ATAI $1.9B, GHRS $1.8B) trade at significantly lower valuations. | Low |
| Technical trend | Strong uptrend from $8 52-week low to $47. RSI likely overbought after the Phase 3 gap-up. The stock is near the $49.20 all-time high with elevated volume. | Medium |
| Risk level | Extremely high. Pre-revenue, FDA approval binary risk, psychedelic therapy regulatory/political risk, single-pipeline concentration ($805M raise priced at ~$47), cash burn, dilution, and competition from CMPS, ATAI, and GH Research. | Medium-high |
| AI confidence | Medium-low confidence. Financial data is reliable, technical levels are observable, and risk categories are clear. Pipeline probability, FDA approval likelihood, and commercial revenue estimates are inherently speculative. | Medium-low data confidence |
| Investment certainty | Low certainty. Definium has a positive catalyst but no approved products, no revenue, and a binary regulatory path. The stock has already priced in significant optimism after the Phase 3 win. | Low |
DFTX AI stock forecast
The DFTX AI stock forecast uses scenario ranges around the $47.07 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires FDA approval of DT120, commercial success in MDD and GAD, and pipeline expansion. The base case assumes approval with moderate commercial uptake. The bearish case assumes FDA rejection, clinical setbacks, or failed commercialization. Traditional EPS-based valuation is not applicable as DFTX is pre-revenue.
$75 to $95
More likely if DT120 receives FDA approval with a broad label for MDD and GAD, commercial launch exceeds expectations, pipeline candidates (DT402 for ASD) show positive data, and the market assigns a premium multiple reflecting blockbuster potential.
$45 to $60
More likely if DT120 receives FDA approval with a narrow label, commercial uptake is moderate, cash burn continues at current rates, and the stock trades in line with analyst targets averaging $57.
$15 to $25
More likely if the FDA requires additional trials, DT120 approval is delayed or denied, Phase 4 or REMS requirements limit commercial potential, DT402 trials fail, or the competitive landscape shifts unfavorably.
DFTX AI technical analysis
DFTX AI technical analysis starts from the $47.07 close on July 10, 2026 used for this July 12 static page. The stock rallied sharply from a $7.96 52-week low to a $49.20 high following the Phase 3 Emerge study results in late June 2026. Trading volume spiked to over 10 million shares on the announcement day compared to the 2.9 million average. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $47.07 | Latest verified close used for this page as of the July 12, 2026 data cutoff, based on Google Finance and Yahoo Finance data. |
| Near support | $42.00 to $45.00 | Support zone around the post-Phase-3 gap fill area. A retracement to this level would test whether the rally is sustainable. |
| Secondary support | $30.00 to $35.00 | Pre-Phase-3 trading range. A break below this level would suggest the catalyst has been fully priced out. |
| Near resistance | $49.20 to $50.00 | The 52-week and all-time high zone. A breakout above $49.20 on volume would signal trend continuation. |
| Volume profile | 2.9 million avg, peaked at 10M+ | Volume spiked to over 10 million shares on the Phase 3 announcement day, well above the 2.9 million 20-day average. Sustained elevated volume supports the breakout. |
| Momentum | RSI likely overbought above 70 | After a 5x rally from the 52-week low, RSI is likely in overbought territory. A consolidation or pullback would be normal before the next directional move. |
| Volatility | Beta 2.20 | With a beta of 2.20, DFTX is more than twice as volatile as the S&P 500. Position sizing must account for daily swings of 5-10% being normal. |
| Invalidation | Close below $42.00, then $30.00 | A close below the $42 support zone would suggest the post-Phase-3 gap is being filled. A break below $30 would indicate a complete reversal of the catalyst-driven rally. |
DFTX AI trading strategy
The DFTX AI trading strategy is a rules-based framework, not personalized advice. It combines catalyst awareness, technical confirmation, position sizing for a high-volatility pre-revenue biotech, and clear invalidation levels. Biotech binary events (FDA decisions, clinical data) can produce gap moves of 50% or more.
Monitor FDA communication milestones for DT120 NDA submission and review timelines. Look for price consolidation above $45 with declining volatility as a constructive pattern. The next major catalyst is the FDA acceptance of the NDA filing.
Do not add exposure ahead of binary events without defined risk limits. A close below $42 with volume suggests the post-Phase-3 momentum has faded.
If DFTX pulls back toward the $42-$45 support zone on normal volume without negative news, compare the risk-reward of the base case analyst target near $57. The wide bid-ask spread (34.15 bid / 57.43 ask) signals illiquidity risk.
Limit position size given the beta of 2.20 and the possibility of gap moves on FDA news. Do not risk more than a defined percentage of portfolio on any single biotech position.
Track DT120 NDA submission and FDA acceptance, any FDA Advisory Committee meeting schedule, DT402 Phase 2a data readout for ASD, quarterly cash burn and runway updates, and analyst rating changes.
Reduce or exit if the FDA issues a Complete Response Letter, if cash runway shortens without a financing plan, or if the stock loses the $30 support level on negative news.
Investment research summary
Definium Therapeutics is developing LSD-based (DT120) and MDMA-based (DT402) prescription therapies for brain health disorders including MDD, GAD, PTSD, and ASD. The company has no approved products, no revenue, and its entire valuation depends on successful clinical development and FDA approval.
The potential moat rests on patent-protected formulations (DT120 ODT, DT402 R-enantiomer), FDA regulatory barriers for Schedule I substances, and first-mover positioning in the emerging psychedelic therapy market. The moat is unproven and could be eroded by competing platforms from Compass Pathways, AtaiBeckley, or GH Research.
The thesis fails if DT120 fails to secure FDA approval, receives a narrow label limiting commercial potential, if DT402 ASD trials miss endpoints, if the FDA imposes restrictive REMS that limit patient access, if insurance reimbursement is inadequate, or if competitors bring superior therapies to market first.
CEO Robert Barrow leads a team that successfully navigated the company through its rename from MindMed to Definium, secured a positive Phase 3 readout, and raised $805 million in an upsized public offering. The key question is whether management can execute the NDA submission, FDA negotiation, and commercial launch phases.
Psychedelic medicine is emerging as a potential paradigm shift in mental health treatment, with growing FDA acceptance (Spravato approved, MDMA-assisted therapy nearing approval) and increasing public awareness of the limitations of current antidepressants. Definium may benefit from this long-term secular trend if it can achieve approval and commercial scale.
At $6.25 billion market cap with no revenue or earnings, Definium trades at a premium to psychedelic biotech peers (CMPS ~$900M, ATAI ~$1.9B, GHRS ~$1.8B). The valuation reflects the Phase 3 success and the larger TAM for DT120 in MDD and GAD. The margin of safety is low given the binary approval risk.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DFTX price | $47.07 close on July 10, 2026 | Google Finance and Yahoo Finance quote snapshots | July 12, 2026 |
| Market capitalization | $6.25 billion, verified as $47.07 x 132.74 million shares | financial_rigor.py market cap verification and Google Finance | July 12, 2026 |
| Shares outstanding | 132.74 million (post-offering) | Google Finance | July 12, 2026 |
| Cash and cash equivalents | $373 million (mrq) | Yahoo Finance balance sheet data | July 12, 2026 |
| Q1 2026 net loss | -$77.1 million | Google Finance income statement data (cross-verified with Yahoo Finance, deviation 0%) | July 12, 2026 |
| TTM net loss | -$237.5 million | Calculated from Google Finance quarterly income statement data | July 12, 2026 |
| EPS (TTM) | -$2.49 | Google Finance summary data | July 12, 2026 |
| R&D expense Q1 2026 | $41.5 million | Google Finance income statement data | July 12, 2026 |
| Valuation metrics | P/B 22.41x, no PE (negative earnings), no PS (no revenue). Pipeline-based valuation only. | financial_rigor.py valuation verification | July 12, 2026 |
| Analyst consensus | 12 analysts, all Buy. Average target $56.83 (range $35-$74) | Google Finance analyst ratings | July 12, 2026 |
| 52-week range | $7.96 - $49.20 | Yahoo Finance statistics data | July 12, 2026 |
| Beta | 2.20 | Yahoo Finance statistics data and Google Finance | July 12, 2026 |
This DFTX AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong. Definium Therapeutics is a pre-revenue clinical-stage biotech with binary regulatory risk.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
